GSK
GSKDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Execution on late‑stage pipeline readouts and positive FY2026 guidance drive re-rating to analyst high (near $53); successful commercial traction and favorable regulatory outcomes widen multiples.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.4.
What can break
Adverse clinical or regulatory outcomes for key pipeline assets
Momentum
29
Value
67
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.50 · Bull $53.00 · Bear $15.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $56.87
Why
Momentum29 · Δ7d +4.8
Value67 · Δ7d +0.4
Sentiment28 · Δ7d +6.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
29
34% active weight
Current posture
7d trendSoftening
Δ7d
+4.8
Δ21d
+5.9
Value
67
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.5
Sentiment
28
33% active weight
Current posture
7d trendImproving
Δ7d
+6.1
Δ21d
+7.4
Why this grade
Composite grade D. Momentum 29.5 / Value 67.4 / Sentiment 28.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$98.3B
Beta
0.68
Shares Out
4.08B
P/E (TTM)
13.6
P/S (TTM)
2.31
P/FCF (TTM)
34.24
Rev YoY
+6.7%
EPS YoY
+3551.1%
Gross Margin
+72.5%
Op Margin
+23.4%
Net Debt
$16.96B
Current Ratio
0.84
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology